Ms. Barrett is a highly regarded industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies.
Ms. Barrett has served as director and our President and Chief Executive Officer since January 2019. Prior to UroGen, Ms. Barrett was CEO of Novartis Oncology and a member of the Novartis Executive Committee since February 2018.
Prior to Novartis, Ms. Barrett served at Pfizer, Inc. in various leadership capacities, most recently as the Global President of Oncology and, before that, as President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and Regional President of United States Oncology.
Before Pfizer, Ms. Barrett held positions at Cephalon, Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson & Johnson. She started her career at Kraft Foods Group, Inc.
Ms. Barrett also currently serves on the boards of directors of Sage Therapeutics and Allogene Therapeutics.
Ms. Barrett received an M.B.A. degree in Marketing from Saint Joseph’s University and a B.S. from the University of Louisiana.
What is Elizabeth A. Barrett's net worth?
The estimated net worth of Elizabeth A. Barrett is at least $2.72 million as of December 14th, 2020. Ms. Barrett owns 229,117 shares of UroGen Pharma stock worth more than $2,717,328 as of November 14th. This net worth estimate does not reflect any other investments that Ms. Barrett may own. Additionally, Ms. Barrett receives an annual salary of $1,340,000.00 as CEO at UroGen Pharma. Learn More about Elizabeth A. Barrett's net worth.
How old is Elizabeth A. Barrett?
What is Elizabeth A. Barrett's salary?
How do I contact Elizabeth A. Barrett?
Has Elizabeth A. Barrett been buying or selling shares of UroGen Pharma?
Elizabeth A. Barrett has not been actively trading shares of UroGen Pharma within the last three months. Most recently, Elizabeth A. Barrett sold 8,195 shares of the business's stock in a transaction on Monday, January 31st. The shares were sold at an average price of $7.58, for a transaction totalling $62,118.10. Learn More on Elizabeth A. Barrett's trading history.
Who are UroGen Pharma's active insiders?
Are insiders buying or selling shares of UroGen Pharma?
In the last twelve months, insiders at the sold shares 6 times. They sold a total of 28,315 shares worth more than $405,360.32. The most recent insider tranaction occured on September, 9th when insider Mark Schoenberg sold 859 shares worth more than $11,235.72. Insiders at UroGen Pharma own 5.1% of the company.
Learn More about insider trades at UroGen Pharma. Information on this page was last updated on 9/9/2024.
